Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

114825

registered interest
date	05/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to sections 105 and 120 of NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review, published in November 2014, which members of (a) NHS England's staff and (b) the Clinical Reference Group made up the project team; from where the focus group was drawn; and what the names are of those who sat on that focus group.
tabling member constituency	Wells
tabling member printed	Tessa Munt
uin	213582
answer	answer is ministerial correction date of answer 10/11/2014 answer text <p>The Walton Centre NHS Foundation Trust, based in Liverpool, provided the cost information referenced in Section 121 of NHS England's <em>Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review</em>, published on 3 November 2014.</p><p> </p><p> </p><p> </p><p>Two separate consultation (focus group) meetings were held and chaired by Mr Sean Duffy, NHS England’s National Clinical Director for Cancer, involving members of the Radiotherapy Clinical Reference Group (CRG), Adult Neurosurgery CRG, Brain and Central Nervous System CRG, Neurosciences CRG and Stereotactic Radiosurgery CRG to agree key principles and options. Details of the membership of each of the CRGs are set out on the NHS England website at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/d-com/spec-serv/crg/" target="_blank">http://www.england.nhs.uk/ourwork/d-com/spec-serv/crg/</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 213583 question first answered 10/11/2014 17:16:16 answering member 3918 label Biography information for Jane Ellison
tabling member	4089 label Biography information for Tessa Munt

114828

registered interest
date	05/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to section 121 of NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review, published in November 2014, what the names are of those who supplied the data demonstrating (a) the cost effectiveness of treating patients surgically as against treating with stereotactic radiosurgery, (b) the cost of providing surgical treatment and (c) the cost of providing stereotacic radiosurgery.
tabling member constituency	Wells
tabling member printed	Tessa Munt
uin	213583
answer	answer is ministerial correction date of answer 10/11/2014 answer text <p>The Walton Centre NHS Foundation Trust, based in Liverpool, provided the cost information referenced in Section 121 of NHS England's <em>Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review</em>, published on 3 November 2014.</p><p> </p><p> </p><p> </p><p>Two separate consultation (focus group) meetings were held and chaired by Mr Sean Duffy, NHS England’s National Clinical Director for Cancer, involving members of the Radiotherapy Clinical Reference Group (CRG), Adult Neurosurgery CRG, Brain and Central Nervous System CRG, Neurosciences CRG and Stereotactic Radiosurgery CRG to agree key principles and options. Details of the membership of each of the CRGs are set out on the NHS England website at the following link:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/d-com/spec-serv/crg/" target="_blank">http://www.england.nhs.uk/ourwork/d-com/spec-serv/crg/</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 213582 question first answered 10/11/2014 17:16:16 answering member 3918 label Biography information for Jane Ellison
tabling member	4089 label Biography information for Tessa Munt

114831

registered interest
date	05/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to NHS England's agreement to provide £6 million of funding for Cancer Research UK's Stereotactic Ablative Radiotherapy (SABR) clinical trial programme, (a) over what time period that funding will be available, (b) how many patients in total will take part in that trial, (c) how many of those patients will receive SABR and (d) what the cost per patient will be.
tabling member constituency	Wells
tabling member printed	Tessa Munt
uin	213584
answer	answer is ministerial correction date of answer 10/11/2014 answer text <p>The majority of the trials in the Cancer Research UK (CRUK) Stereotactic Ablative Radiotherapy (SABR) clinical trial programme run over three years, although some extend to five.</p><p> </p><p> </p><p> </p><p>CRUK has approved five United Kingdom-wide trials to date, and a sixth is being considered in November 2014. The current assessment of the number of patients that will be recruited to the trials is a provisional estimate and it is important to note that this will vary dependent on a number of factors, including local recruitment and randomisation to different trial arms.</p><p> </p><p> </p><p> </p><p>The current trial protocols indicate that around two thirds of patients will be allocated to SABR trial arms.</p><p> </p><p> </p><p> </p><p>NHS England is providing a package of support of up to £6 million to trusts that are participating in the CRUK trials. The support package for SABR, for each participating trust will vary dependent on the fractionation used within the trial, but has been developed using the existing tariff structure for external beam radiotherapy as its basis.</p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/11/2014 16:05:22 answering member 3918 label Biography information for Jane Ellison
tabling member	4089 label Biography information for Tessa Munt

114838

registered interest
date	05/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Vitamin D
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects the (a) interim and (b) final report from the Scientific Advisory Committee on Nutrition Vitamin D Working Group to be published.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	213660
answer	answer is ministerial correction date of answer 10/11/2014 answer text <p>The Scientific Advisory Committee on Nutrition aims to publish its draft review of the dietary reference values for vitamin D for public consultation in spring 2015, and to publish the finalised report by the end of 2015.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/11/2014 16:07:41 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

114840

registered interest
date	05/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, pursuant to his Answer of 23 October 2014 to Question 211147, what the timeline is for publication of the Liver Disease Framework under development by Public Health England; and whether there will be a full public consultation during that process.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	213661
answer	answer is ministerial correction date of answer 10/11/2014 answer text <p>Public Health England plans to publish its framework for tackling liver disease in the summer of 2015.</p><p> </p><p> </p><p> </p><p>The framework will lay out clearly the scope of Public Health England activities. This will range from the investigation of hepatitis viruses to support local authorities in their work to tackle the effects of alcohol consumption and obesity on liver disease. It will also cover the life course from antenatal screening, vaccination of babies born, to mothers with chronic Hepatitis B, to improving the care of patients dying from liver disease.</p><p> </p><p> </p><p> </p><p>Public Health England is not intending to hold a formal consultation on the framework but is conducting extensive engagement with a wide range of stakeholders in its development. These include NHS England, the liver disease related charities, hepatologists (liver disease specialists) from across the country and local authority representatives.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/11/2014 17:08:11 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

114842

registered interest
date	05/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Alcoholic Drinks
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when he expects the second interim report on the 2013 data on progress that has been made towards the Public Health Responsibility Deal Alcohol Network pledge to remove one billion units of alcohol from the market by the end of 2015 will be published.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	213662
answer	answer is ministerial correction date of answer 10/11/2014 answer text <p>The publication “Responsibility Deal: Monitoring the number of units of alcohol sold - second interim report, 2013 data” will be published by the Department in December 2014. The exact date will be announced four weeks prior to publication on GOV.UK</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/11/2014 16:06:30 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

114843

registered interest
date	05/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Bladder Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he has taken to ensure that there are adequate supplies of BCG vaccine available for the treatment of bladder cancer.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	213658
answer	answer is ministerial correction date of answer 10/11/2014 answer text <p>The shortage of BCG for bladder instillation, which has arisen due to manufacturing problems, is affecting countries worldwide. The Department is working closely with the suppliers to help ensure that supplies are available for United Kingdom patients. We are also in close contact with the British Association of Urological Surgeons who have issued advice for clinicians.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/11/2014 16:02:51 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

106319

registered interest
date	04/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review published in November 2014 is solely for the purpose of assessing the needs of intracranial radiotherapy treatment in England.
tabling member constituency	Wells
tabling member printed	Tessa Munt
uin	213359
answer	answer is ministerial correction date of answer 07/11/2014 answer text <p>NHS England’s review is concerned with assessing and meeting the need for the treatment of intracranial conditions with SRS/SRT; fractionated extracranial radiotherapy and Stereotactic Ablative Radiotherapy (SABR) are not included in the review.</p><p> </p><p><strong> </strong></p><p> </p><p>The two activity scenarios in the consultation document assume a significant growth in treatment rates. Scenario A is based on the level of need identified in the NHS England Clinical Commissioning Policies, whilst scenario B is based on an expected growth demand based on the treatment rates of some other European countries. The relative merits of these two scenarios are laid out from page eight of the consultation document</p><p> </p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change/supporting_documents/srssrtconsultguide021114.pdf</p><p> </p><p> </p><p> </p><p>NHS England’s reasons for recommending scenario A with a seven-day working week, ‘Option 2’, is set out in their report as follows:</p><p> </p><p> </p><p> </p><p>“SCOG [the Specialised Commissioning Oversight Group] decided on Option 2 as the preferred option as it is based on seven-day working, which aligns to the national strategic direction of moving towards seven-day service provision. Additionally, the risk of overcapacity is minimised if clinical trends change more slowly than expected because the centres providing the service could revert to fewer days per week. The avoidance of machines lying idle 2/7ths of the week will ensure best price for the NHS. Option 2 could be superseded by further expansion of national capacity should the activity levels increase beyond those described in Scenario A.”</p><p> </p><p> </p><p> </p><p>“It was recognised that in planning for Option 2, future increases in capacity would still be possible should activity levels rise beyond those described in Scenario A, in order to mitigate any risk of future under-capacity”</p><p> </p><p> </p><p> </p><p>The national recommendation that a minimum number patients be treated each year relates specifically to Stereotactic Ablative Radiotherapy (SABR) which is out of the scope of this consultation.</p><p> </p><p> </p><p> </p><p>NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review is currently subject to an ongoing public consultation, which closes on 26 January 2015. NHS England would welcome any detailed comments being fed directly into the consultation process, including on data sources. Comments can be made at this link:</p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 213360 213361 213362 question first answered 07/11/2014 13:57:03 answering member 3918 label Biography information for Jane Ellison
tabling member	4089 label Biography information for Tessa Munt

106320

registered interest
date	04/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Brain: Tumours
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review published in November 2014, what evidence NHS England has received that demonstrates that instances of both malignant and benign brain tumours are lower in England than in other devoloped countries; and for what reasons NHS England is supporting proposals which will prevent the NHS from adopting a programme to allow it to reach parity with other developed countries for the provision of stereotactic radiotherapy for brain tumours.
tabling member constituency	Wells
tabling member printed	Tessa Munt
uin	213360
answer	answer is ministerial correction date of answer 07/11/2014 answer text <p>NHS England’s review is concerned with assessing and meeting the need for the treatment of intracranial conditions with SRS/SRT; fractionated extracranial radiotherapy and Stereotactic Ablative Radiotherapy (SABR) are not included in the review.</p><p> </p><p><strong> </strong></p><p> </p><p>The two activity scenarios in the consultation document assume a significant growth in treatment rates. Scenario A is based on the level of need identified in the NHS England Clinical Commissioning Policies, whilst scenario B is based on an expected growth demand based on the treatment rates of some other European countries. The relative merits of these two scenarios are laid out from page eight of the consultation document</p><p> </p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change/supporting_documents/srssrtconsultguide021114.pdf</p><p> </p><p> </p><p> </p><p>NHS England’s reasons for recommending scenario A with a seven-day working week, ‘Option 2’, is set out in their report as follows:</p><p> </p><p> </p><p> </p><p>“SCOG [the Specialised Commissioning Oversight Group] decided on Option 2 as the preferred option as it is based on seven-day working, which aligns to the national strategic direction of moving towards seven-day service provision. Additionally, the risk of overcapacity is minimised if clinical trends change more slowly than expected because the centres providing the service could revert to fewer days per week. The avoidance of machines lying idle 2/7ths of the week will ensure best price for the NHS. Option 2 could be superseded by further expansion of national capacity should the activity levels increase beyond those described in Scenario A.”</p><p> </p><p> </p><p> </p><p>“It was recognised that in planning for Option 2, future increases in capacity would still be possible should activity levels rise beyond those described in Scenario A, in order to mitigate any risk of future under-capacity”</p><p> </p><p> </p><p> </p><p>The national recommendation that a minimum number patients be treated each year relates specifically to Stereotactic Ablative Radiotherapy (SABR) which is out of the scope of this consultation.</p><p> </p><p> </p><p> </p><p>NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review is currently subject to an ongoing public consultation, which closes on 26 January 2015. NHS England would welcome any detailed comments being fed directly into the consultation process, including on data sources. Comments can be made at this link:</p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 213359 213361 213362 question first answered 07/11/2014 13:57:04 answering member 3918 label Biography information for Jane Ellison
tabling member	4089 label Biography information for Tessa Munt

106321

registered interest
date	04/11/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review published in November 2014, section 58, how NHS England is able accurately to protect the growth requirements for stereotactic radiosurgery if the data source it is using does not allow it to draw firm conclusions for the purposes of this Review.
tabling member constituency	Wells
tabling member printed	Tessa Munt
uin	213361
answer	answer is ministerial correction date of answer 07/11/2014 answer text <p>NHS England’s review is concerned with assessing and meeting the need for the treatment of intracranial conditions with SRS/SRT; fractionated extracranial radiotherapy and Stereotactic Ablative Radiotherapy (SABR) are not included in the review.</p><p> </p><p><strong> </strong></p><p> </p><p>The two activity scenarios in the consultation document assume a significant growth in treatment rates. Scenario A is based on the level of need identified in the NHS England Clinical Commissioning Policies, whilst scenario B is based on an expected growth demand based on the treatment rates of some other European countries. The relative merits of these two scenarios are laid out from page eight of the consultation document</p><p> </p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change/supporting_documents/srssrtconsultguide021114.pdf</p><p> </p><p> </p><p> </p><p>NHS England’s reasons for recommending scenario A with a seven-day working week, ‘Option 2’, is set out in their report as follows:</p><p> </p><p> </p><p> </p><p>“SCOG [the Specialised Commissioning Oversight Group] decided on Option 2 as the preferred option as it is based on seven-day working, which aligns to the national strategic direction of moving towards seven-day service provision. Additionally, the risk of overcapacity is minimised if clinical trends change more slowly than expected because the centres providing the service could revert to fewer days per week. The avoidance of machines lying idle 2/7ths of the week will ensure best price for the NHS. Option 2 could be superseded by further expansion of national capacity should the activity levels increase beyond those described in Scenario A.”</p><p> </p><p> </p><p> </p><p>“It was recognised that in planning for Option 2, future increases in capacity would still be possible should activity levels rise beyond those described in Scenario A, in order to mitigate any risk of future under-capacity”</p><p> </p><p> </p><p> </p><p>The national recommendation that a minimum number patients be treated each year relates specifically to Stereotactic Ablative Radiotherapy (SABR) which is out of the scope of this consultation.</p><p> </p><p> </p><p> </p><p>NHS England's Stereotactic Radiosurgery and Radiotherapy Services Needs Assessment and Service Review is currently subject to an ongoing public consultation, which closes on 26 January 2015. NHS England would welcome any detailed comments being fed directly into the consultation process, including on data sources. Comments can be made at this link:</p><p> </p><p> </p><p>www.engage.england.nhs.uk/survey/options-for-change</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 213359 213360 213362 question first answered 07/11/2014 13:57:04 answering member 3918 label Biography information for Jane Ellison
tabling member	4089 label Biography information for Tessa Munt